Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Boston Scientific CorpBSX67.768.115.9934.519.32%2.21%39.46$83.84$241.71194,171$84.00

Detail of Boston Scientific Corp

 
CEO
Mr. Michael F. Mahoney
Employees
48000
Industry
Medical Devices
Sector
Healthcare
Market cap
$124B

Company details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OTH
OI
OIE
PI
TAX
NI
Revenue (Rev)
$15.23B
Cost of goods (CoG)
-$4.74B
Gross profit (GP)
$10.49B
Operating expense (OE)
-$6.93B
Research and development (R&D)
-$1.47B
General and administrative (G&A)
-$5.43B
Other (OTH)
-$30.00M
Operating income (OI)
$2.72B
Other income expense (OIE)
-$324.00M
Pretax income (PI)
$2.14B
Tax (TAX)
-$319.00M
Net income (NI)
$1.82B
Boston Scientific Corp
BSX • XNYS • US
$84.00
+31.50 (59.98%)
Stock vs Industry average
  • Industry average

Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
$1.24
Margin profit
12.00%
52 week low
$51.43
52 week high
$88.620003
50-day simple moving average
$84.59
200-day simple moving average
$83.84
Percent held by insiders
0.18%
Percent held by institutions
92.66%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
BSX +59.95%
eps change
BSX +22.22%